Assessment of HIV vaccine development: Past, present, and future

Advances in Pharmacology

Volumn 49, Issue , 2000, Pages 263-314

  Cho, Michael W ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE;

ANIMAL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GLYCOSYLATION; HIV; HIV ENVELOPE PROTEIN GP120; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED; VACCINES, DNA; VARIATION (GENETICS);

EID: 0034564120     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s1054-3589(00)49030-7     Document Type: Article

References (285)

1. G.L. Ada M.J. McElrath HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy AIDS Res. Hum. Retroviruses 13 1997 205 210
2. S. Ahmad B. Lohman M. Marthas L. Giavedoni Z. el-Amad N.L. Haigwood C.J. Scandella M.B. Gardner P.A. Luciw T. Yikma Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus AIDS Res. Hum. Retroviruses 10 1994 195 204
3. N. Almond K. Kent M. Cranage E. Rud B. Clarke E.J. Stott Protection by attenuated simian immunodeficiency virus in macaques against challenge with virusinfected cells Lancet 345 1995 1342 1344
4. N.M. Almond J.L. Heeney AIDS vaccine development in primate models AIDS 12 1998 S133 S140
5. E.D. Anderson L. Thomas J.S. Hayflick G. Thomas Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant J. Biol. Chem. 268 1993 24887 24891
6. L.O. Arthur J.W. Bess Jr E.N. Chertova J.L. Rossio M.T. Esser R.E. Benveniste L.E. Henderson J.D. Lifson Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine AIDS Res. Hum. Retroviruses 14 Suppl. 3 1998 S311 5319
7. L.O. Arthur J.W. Bess Jr R.C.D. Sowder R.E. Benveniste D.L. Mann J.C. Chermann L.E. Henderson Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines Science 258 1992 1935 1938
8. L.O. Arthur J.W. Bess Jr R.G. Urban J.L. Strominger W.R. Morton D.L. Mann L.E. Henderson R.E. Benveniste Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus J. Virol. 69 1995 3117 3124
9. L.O. Arthur J.W. Bess Jr D.J. Waters S.W. Pyle J.C. Kelliher P.L. Nara K. Krohn W.G. Robey A.J. Langlois R.C. Gallo Challenge of chimpanzees ( Pan troglodytes ) immunized with human immunodeficiency virus envelope glycoprotein gp120 J. Virol. 63 1989 5046 5053
10. L.O. Arthur S.W. Pyle P.L. Nara J.W. Bess Jr M.A. Gonda J.C. Kelliher R.V. Gilden W.G. Robey D.P. Bolognesi R.C. Gallo Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine Proc. Natl. Acad. Sci. USA 84 1987 8583 8587
11. T.W. Baba Y.S. Jeong D. Pennick R. Bronson M.F. Greene R.M. Ruprecht Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques Science 267 1995 1820 1825
12. T.W. Baba V. Liska A.H. Khimani N.B. Ray P.J. Dailey D. Penninck R. Bronson M.F. Greene H.M. McClure L.N. Martin R.M. Ruprecht Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques Nat. Med. 5 1999 194 203
13. N.K. Back L. Smit J.J. De Jong W. Keulen M. Schutten J. Goudsmit M. Tersmette An N -glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization Virology 199 1994 431 438
14. M.L. Bagarazzi J.D. Boyer V. Ayyavoo D.B. Weiner Nucleic acid-based vaccines as an approach to immunization against human immunodeficiency virus type-1 Curr. Top. Microbiol. Immunol. 226 1998 107 143
15. D. Baltimore C. Heitman HIV vaccines: Prospects and challenges Sci. Am. 279 1998 98 103
16. J.C. Bandres Q.F. Wang J. O'Leary F. Baleaux A. Amara J.A. Hoxie S. Zolla-Pazner M.K. Gorny Human Immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation J. Virol. 72 1998 2500 2504
17. S.W. Barnett J.M. Klinger B. Doe C.M. Walker L. Hansen A.M. Duliege F.M. Sinangil Prime-boost immunization strategies against HIV AIDS Res. Hum. Retroviruses 14 Suppl. 3 1998 S299 S309
18. N. Barrett G. Eder F. Dorner Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees Biotechnol. Ther. 2 1991 91 106
19. J. Benson C. Chougnet M. Robert-Guroff D. Montefiori P. Markham G. Shearer R.C. Gallo M. Cranage E. Paoletti K. Limbach D. Venzon J. Tartaglia G. Franchini Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV (mac251): Dependence on route of challenge exposure J. Virol. 72 1998 4170 4182
20. E.A. Berger HIV entry and tropism: The chemokine receptor connection AIDS 11 1997 S3 S16
21. P. Berglund M. Quesada-Rolander P. Putkonen G. Biberfeld R. Thorstensson P. Liljestrom Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIVA virus AIDS Res. Hum. Retroviruses 13 1997 1487 1495
22. B. Berkhout K. Verhoef J.L. van Wamel N.K. Back Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains J. Virol. 73 1999 1138 1145
23. L. Berkower G.E. Smith C. Giri D. Murphy Human immunodeficiency virus 1: Predominance of a group-specific neutralizing epitope that persists despite genetic variation J. Exp. Med. 170 1989 1681 1695
24. P.W. Berman Development of bivalent rgp120 vaccines to prevent HIV type 1 infection AIDS Res. Hum. Retroviruses 14 Suppl. 3 1998 S277 S289
25. P.W. Berman T.J. Gregory L. Riddle G.R. Nakamura M.A. Champe J.P. Porter F.M. Wurm R.D. Hershberg E.K. Cobb J.W. Eichberg Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 Nature 345 1990 622 625
26. P.W. Berman J.E. Groopman T. Gregory P.R. Clapham R.A. Weiss R. Ferriani L. Riddle C. Shimasaki C. Lucas L.A. Lasky Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120 Proc. Natl. Acad. Sci. USA 85 1998 5200 5204
27. P.W. Berman K.K. Murthy T. Wrin J.C. Vennari E.K. Cobb D.J. Eastman M. Champe G.R. Nakamura D. Davison M.F. Powell J. Bussiere D.P. Francis T. Matthews T.J. Gregory J.F. Obijeski Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1 J. Infect. Dis. 173 1996 52 59
28. H.B. Bernstein S.P. Tucker E. Hunter J.S. Schutzbach R.W. Compans Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides J. Virol. 68 1994 463 468
29. W.M. Bogers H. Niphuis P. ten Haaft J.D. Laman W. Koornstra J.L. Heeney Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge AIDS 9 1995 F13 F18
30. M.C. Boily B.R. Masse K. Desai M. Alary R.M. Anderson Some important issues in the planning of phase III HIV vaccine efficacy trials Vaccine 17 1999 989 1004
31. A. Bolmstedt A. Hemming P. Flodby P. Berntsson B. Travis J.P. Lin J. Ledbetter T. Tsu H. Wigzell S.L. Hu Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins J. Gen. Virol. 72 1991 1269 1277
32. A. Bolmstedt S. Sjolander J.E. Hansen L. Akerblom A. Hemming S.L. Hu B. Morein S. Olofsson Influence of N-liked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response J. Acq. Immune Defic. Syndr. Hum. Retrovirol. 12 1996 213 220
33. P. Borrow H. Lewicki B.H. Hahn G.M. Shaw M.B. Oldstone Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection J. Virol. 68 1994 6103 6110
34. J.D. Boyer K.E. Ugen B. Wang M. Agadjanyan L. Gilbert M.L. Bagarazzi M. Chattergoon P. Frost A. Javadian W.V. Williams Y. Refaeli R.B. Ciccarelli D. McCallus L. Coney D.B. Weiner Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination Nat. Med. 3 1997 526 532
35. J.D. Boyer B. Wang K.E. Ugen M. Agadjanyan A. Javadian P. Frost K. Dang R.A. Carrano R. Ciccarelli L. Coney W.V. Williams D.B. Weiner In vivo protective anti-HIV immune responses in non-human primates through DNA immunization J. Med. Primatol. 25 1996 242 250
36. C.C. Broder P.L. Earl D. Long S.T. Abedon B. Moss R.W. Doms Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies Proc. Natl. Acad. Sci. USA 91 1994 11699 11703
37. C. Bruck C. Thiriart L. Fabry M. Francotte P. Pala O. Van Opstal J. Clup M. Rosenberg M. De Wilde P. Heidt HIV-1 envelope-elicited neutralizing antibody titres correlate with virus load in chimpanzees Vaccine 12 1994 1141 1148
38. D.R. Burton A vaccine for HIV type 1: the antibody prespective Proc. Natl. Acad. Sci. USA 94 1997 10018 10023
39. T.D. Butters B. Yudkin G.S. Jacob I.M. Jones Structural characterization of the N-linked oligosaccharides derived from HIV gp120 expressed in lepidopteran cells Glycoconj. J. 15 1998 83 88
40. A.J. Cann M.J. Churcher M. Boyd W. O'Brien J.Q. Zhao J. Zack I.S. Chen The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism J. Virol. 66 1992 305 309
41. D.C. Chan D. Fass J.M. Berger P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273
42. B. Chesebro J. Nishio S. Perryman A. Cann W. O'Brien I.S. Chen K. Wehrly Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages J. Virol. 65 1991 5782 5789
43. M.W. Cho M.K. Lee M.C. Carney J.F. Berson R.W. Doms M.A. Martin Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4 J. Virol. 72 1998 2509 2515
44. H. Choe M. Farzan Y. Sun N. Sullivan B. Rollins P.D. Ponath L. Wu C.R. Mackay G. LaRosa W. Newman N. Gerard C. Gerard J. Sodroski The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates Cell 85 1996 1135 1148
45. M.L. Clements-Mann K. Weinhold T.J. Matthews B.S. Graham G.J. Gorse M.C. Keefer M.J. McElrath R.H. Hsieh J. Mestecky S. Zolla-Pazner J. Mascola D. Schwartz R. Siliciano L. Corey P.F. Wright R. Belshe R. Dolin S. Jackson S. Xu P. Fast M.C. Walker D. Stablein J.L. Excter J. Tartaglia E. Paoletti Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group J. Infect. Dis. 177 1998 1230 1246
46. F. Cocchi A.L. DeVico A. Garzino-Demo A. Cara R.C. Gallo P. Lusso The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokinemediated blockade of infection Nat. Med. 2 1996 1244 1247
47. J. Cohen Jitters jeopardize AIDS vaccine trials Science 262 1993 980 981
48. A.J. Conley J.A. Kessler II L.J. Boots P.M. McKenna W.A. Schleif E.A. Emini G.E. Mark III H. Katinger E.K. Cobb S.M. Lunceford S.R. Rouse K.K. Murthy The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate J. Virol. 70 1996 6751 6758
49. R.L. Connor B.T. Korber B.S. Graham B.H. Hahn D.D. Ho B.D. Walker A.U. Neumann S.H. Vermund J. Mestecky S. Jackson E. Fenamore Y. Cao F. Gao S. Kalams K.J. Kunstman D. McDonald N. McWilliams A. Trkola J.P. Moore S.M. Wolinsky Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines J. Virol. 72 1998 1552 1576
50. E.L. Cooney A.C. Collier P.D. Greenberg R.W. Coombs J. Zarling D.E. Arditti M.C. Hoffman S.L. Hu L. Corey Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein Lancet 337 1991 567 572
51. E.L. Cooney M.J. McElrath L. Corey S.L. Hu A.C. Collier D. Arditti M. Hoffman R.W. Coombs G.E. Smith P.D. Greenberg Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein Proc. Natl. Acad. Sci. USA 90 1993 1882 1886
52. L. Corey M.J. McElrath K. Weinhold T. Matthews D. Stablein B. Graham M. Keefer D. Schwartz G. Gorse Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group J. Infect. Dis. 177 1998 301 309
53. M.P. D'Souza V.A. Harden Chemokines and HIV-1 second receptors: Confluence of two fields generates optimism in AIDS research Nat. Med. 2 1996 1293 1300
54. M.D. Daniel F. Kirchhoff S.C. Czajak P.K. Sehgal R.C. Desrosiers Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene Science 258 1992 1938 1941
55. M.D. Daniel G.P. Mazzara M.A. Simon P.K. Sehgal T. Kodama D.L. Panicali R.C. Desrosiers High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection AIDS Res. Hum. Retroviruses 10 1994 839 851
56. D. Davis D.M. Stephens C. Willers P.J. Lachmann Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gpl20 of human immunodeficiency virus type 1 J. Gen. Virol. 71 1990 2889 2898
57. J.J. De Jong J. Goudsmit W. Keulen B. Klaver W. Krone M. Tersmette A. de Ronde Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity J. Virol. 66 1992 757 765
58. N.J. Deacon A. Tsykin A. Solomon K. Smith M. Ludford-Menting D.J. Hooker D.A. McPhee A.L. Greenway A. Ellett C. Chatfield Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients Science 270 1995 988 991
59. E. Decroly M. Vandenbranden J.M. Ruysschaert J. Cogniaux G.S. Jacob S.C. Howard G. Marshall A. Kompelli A. Basak F. Jean The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-1 TM) J. Biol. Chem. 269 1994 12240 12247
60. R.C. Desrosiers M.S. Wyand T. Kodama D.J. Ringler L.O. Arthur P.K. Sehgal N.L. Letvin N.W. King M.D. Danial Vaccine protection against simian immunodeficiency virus infection Proc. Natl. Acad. Sci. USA 86 1989 6353 6357
61. B. Doe K.S. Steimer C.M. Walker Induction of HIV-1 envelope (gpl20)specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans Eur. J. Immunol. 24 1994 2369 2376
62. R. Dolin Human studies in the development of human immunodeficiency virus vaccines J. Infect. Dis. 172 1995 1175 1183
63. R.W. Doms P.L. Earl B. Moss The assembly of the HIV-1 env glycoprotein into dimers and tetramers Adv. Exp. Med. Biol. 300 1991 203 219
64. B.J. Doranz J.F. Berson J. Rucker R.W. Doms Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1) Immunol. Res. 16 1997 15 28
65. C.S. Dunn B. Hurtrel C. Beyer L. Gloeckler T.N. Ledger C. Moog M.P. Kieny M. Mehtali D. Schmitt J.P. Gut A. Kirn A.M. Aubertin Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1 AIDS Res. Hum. Retroviruses 13 1997 913 922
66. W.B. Dyer G.S. Ogg M.A. Demoitie X. Jin A.F. Geczy S.L. Rowland-Jones A.J. McMichael D.F. Nixon J.S. Sullivan Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1 J. Virol. 73 1999 436 443
67. P.L. Earl C.C. Broder D. Long S.A. Lee J. Peterson S. Chakrabarti R.W. Doms B. Moss Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities J. Virol. 68 1994 3015 3026
68. P.L. Earl R.W. Doms B. Moss Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein Proc. Natl. Acad. Sci. USA 87 1990 648 652
69. M.A. Egan W.A. Pavlat J. Tartaglia E. Paoletti K.J. Weinhold M.L. Clements R.F. Siliciano Induction of human immunodeficiency virus type 1 (HIV-1)specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, hostrange-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene J. Infect. Dis. 171 1995 1623 1627
70. E.A. Emini P.L. Nara W.A. Schleif J.A. Lewis J.P. Davide D.R. Lee J. Kessler S. Conley S. Matsushita S.D. Putney Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees J. Virol. 64 1990 3674 3678
71. E.A. Emini W.A. Schleif J.H. Nunberg A.J. Conley Y. Eda S. Tokiyoshi S.D. Putney S. Matsushita K.E. Cobb C.M. Jett Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody Nature 355 1992 728 730
72. E.A. Emini W.A. Schleif J.C. Quintero P.G. Conard J.W. Eichberg G.P. Vlasuk E.D. Lehman M.A. Polokoff T.F. Schaeffer L.D. Schultz Yeastexpressed p55 precursor core protein of human immunodeficiency virus type I does not elicit protective immunity in chimpanzees AIDS Res. Hum. Retroviruses 6 1990 1247 1250
73. J.L. Excler S. Plotkin The prime-boost concept applied to HIV preventive vaccines AIDS 11 1997 S127 S137
74. B. Fazekas de St Groth R.G. Webster Disquisitions on original antigenic sin. I. Evidence in man J. Exp. Med 124 1966 331 345
75. T. Feizi M. Larkin AIDS and glycosylation Glycobiology 1 1990 17 23
76. C. Fennie L.A. Lasky Model for intracellular folding of the human immunodeficiency virus type 1 gp120 J. Virol. 63 1989 639 646
77. E. Fenouillet J.C. Gluckman I.M. Jones Functions of HIV envelope glycans Trends Biochem. Sci. 19 1994 65 70
78. G. Ferrari W. Humphrey M.J. McElrath J.L. Excler A.M. Duliege M.L. Clements L.C. Corey D.P. Bolognesi K.J. Weinhold Clade B-based HIV-1 vaccines elicit cross-Cade cytotoxic T lymphocyte reactivities in uninfected volunteers Proc. Natl. Acad. Sci. USA 94 1997 1396 1401
79. B. Fleury G. Janvier G. Pialoux F. Buseyne M.N. Robertson J. Tartaglia E. Paoletti M.P. Kieny J.L. Excler Y. Riviere Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160 J. Infect. Dis. 174 1996 734 738
80. T.R. Fouts J.M. Binley A. Trkola J.E. Robinson J.P. Moore Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex J. Virol. 71 1997 2779 2785
81. D.P. Francis T. Gregory M.J. McElrath R.B. Belshe G.J. Gorse S. Migasena D. Kitayaporn P. Pitisuttitham T. Matthews D.H. Schwartz P.W. Berman Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3 AIDS Res. Hum. Retroviruses 14 Suppl 3 1998 S325 S331
82. Freed E. O., and Martin, M. A. (in press). The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270 , 23883–23886.
83. E.O. Freed M.A. Martin The molecular and biological properties of the human immunodeficiency virus G. Stamatoyannopoulos A. Neinhuis P. Majerus M. Varmus The Molecular Basis of Blood Diseases 3rd ed. 1999 W.B. Saunders New York
84. D.H. Fuller M.M. Corb S. Barnett K. Steimer J.R. Haynes Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques Vaccine 15 1997 924 926
85. D.H. Fuller M. Murphey-Corb J. Clements S. Barnett J.R. Haynes Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination J. Med. Primatol. 25 1996 236 241
86. D.H. Fuller L. Simpson K.S. Cole J.E. Clements D.L. Panicali R.C. Montelaro M. Murphey-Corb J.R. Haynes Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV Immunol. Cell. Biol. 75 1997 389 396
87. P.N. Fultz P. Nara F. Barre-Sinoussi A. Chaput M.L. Greenberg E. Muchmore M.P. Kieny M. Girard Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells Science 256 1992 1687 1690
88. F. Gao E. Bailes D.L. Robertson Y. Chen C.M. Rodenburg S.F. Michael L.B. Cummins L.O. Arthur M. Peeters G.M. Shaw P.M. Sharp B.H. Hahn Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes Nature 397 1999 436 441
89. M.C. Gauduin P.W. Parren R. Weir C.F. Barbas D.R. Burton R.A. Koup Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 Nat. Med. 3 1997 1389 1393
90. L.D. Giavedoni V. Planelles N.L. Haigwood S. Ahmad J.D. Kluge M.L. Marthas M.B. Gardner P.A. Luciw T.D. Yilma Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection J. Virol. 67 1993 577 583
91. M. Girard M.P. Kieny A. Pinter F. Barre-Sinoussi P. Nara H. Kolbe K. Kusumi A. Chaput T. Reinhart E. Muchmore Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus Proc. Natl. Acad. Sci. USA 88 1991 542 546
92. M. Girard B. Meignier F. Barre-Sinoussi M.P. Kieny T. Matthews E. Muchmore P.L. Nara Q. Wei L. Rimsky K. Weinhold Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69 1995 6239 6248
93. M. Girard E. van der Ryst F. Barre-Sinoussi P. Nara J. Tartaglia E. Paoletti C. Blondeau M. Jennings F. Verrier B. Meignier P.N. Fultz Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus Virology 232 1997 98 104
94. M. Girard L. Yue F. Barre-Sinoussi E. van der Ryst B. Meignier E. Muchmore P.N. Fultz Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain J. Virol. 70 1996 8229 8233
95. H. Golding M.P. D'Souza J. Bradac B. Mathieson P. Fast Neutralization of HIV-1 AIDS Res. Hum. Retroviruses 10 1994 633 643
96. M.K. Gorny J.P. Moore A.J. Conley S. Karwowska J. Sodroski C. Williams S. Burda L.J. Boots S. Zolla-Pazner Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 J. Virol. 68 1994 8312 8320
97. G.J. Gorse G.B. Patel F.K. Newman R.B. Belshe P.W. Berman T.J. Gregory T.J. Matthews Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines: The NIAID AIDS Vaccine Evaluation Group Clin. Diagn. Lab. Immunol. 3 1996 378 386
98. F. Gotch Cross-clade T cell recognition of HIV.1 Curr. Opin. Immunol. 10 1998 388 392
99. J. Goudsmit Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts AIDS 2 1988 S41 S45
100. J. Goudsmit C. Thiriart L. Smit C. Bruck C.J. Gibbs Temporal development of cross-neutralization between HTLV-IIIB and HTLV-III RF in experimentally infected chimpanzees Vaccine 6 1988 229 232
101. B.S. Graham Serological responses to candidate AIDS vaccines AIDS Res. Hum. Retroviruses 10 1994 S145 S148
102. B.S. Graham R.B. Belshe M.L. Clements R. Dolin L. Corey P.F. Wright G.J. Gorse K. Midthun M.C. Keefer N.J. Roberts Jr. Vaccination of vaccinianaive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial: The AIDS Vaccine Clinical Trials Network J. Infect. Dis. 166 1992 244 252
103. B.S. Graham G.J. Gorse D.H. Schwartz M.C. Keefer M.J. McElrath T.J. Matthews P.F. Wright R.B. Belshe M.L. Clements R. Dolin Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus: The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network J. Infect. Dis. 170 1994 782 786
104. B.S. Graham T.J. Matthews R.B. Belshe M.L. Clements R. Dolin P.F. Wright G.J. Gorse D.H. Schwartz M.C. Keefer D.P. Bolognesi Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults: The NIAID AIDS Vaccine Clinical Trials Network J. Infect. Dis. 167 1993 533 537
105. B.S. Graham M.J. McElrath R.L. Connor D.H. Schwartz G.J. Gorse M.C. Keefer M.J. Mulligan T.J. Matthews S.M. Wolinsky D.C. Montefiori S.H. Vermund J.S. Lambert L. Corey R.B. Belshe R. Dolin P.F. Wright B.T. Korber M.C. Wolff P.E. Fast Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines: AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group J. Infect. Dis. 177 1998 310 319
106. G.J. Gram A. Hemming A. Bolmstedt B. Jansson S. Olofsson L. Akerblom J.O. Nielsen J.E. Hansen Identification of an N-linked glycan in the Vl-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4 Arch. Virol. 139 1994 253 261
107. T.C. Greenough J.L. Sullivan R.C. Desrosiers Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1 N. Engl. J. Med. 340 1999 236 237
108. R.A. Gruters J.J. Neefjes M. Tersmette R.E. de Goede A. Tulp H.G. Huisman F. Miedema H.L. Ploegh Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase Nature 330 1987 74 77
109. N.L. Haigwood P.L. Nara E. Brooks G.A. Van Nest G. Ott K.W. Higgins N. Dunlop C.J. Scandella J.W. Eichberg K.S. Steimer Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons J. Virol. 66 1992 172 182
110. N.L. Haigwood C.C. Pierce M.N. Robertson A.J. Watson D.C. Montefiori M. Rabin J.B. Lynch L. Kuller J. Thompson W.R. Morton R.E. Benveniste S.L. Hu P. Greenberg S.P. Mossman Protection from pathogenic SIV challenge using multigenic DNA vaccines Immunol. Lett. 66 1999 183 188
111. N.L. Haigwood S. Zolla-Pazner Humoral immunity to HIV, SIV, and SHIV AIDS 12 1998 S121 5132
112. S. Hallenberger V. Bosch H. Angliker E. Shaw H.D. Klenk W. Garten Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160 Nature 360 1992 358 361
113. B.F. Haynes G. Pantaleo A.S. Fauci Toward an understanding of the correlates of protective immunity of HIV infection Science 271 1996 324 328
114. J.L. Heeney Primate models for AIDS vaccine development AIDS 10 1996 S115 S122
115. J.L. Heeney C. Bruck J. Goudsmit L. Montagnier A. Schultz D. Tyrrell S. Zolla-Pazner Immune correlates of protection from HIV infection and AIDS Immunol. Today 18 1997 4 8
116. J.L. Heeney P. de Vries R. Dubbes W. Koornstra H. Niphuis P. ten Haaft J. Boes M.E. Dings B. Morein A.D. Osterhaus Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines J. Med. Primatol. 21 1992 126 130
117. A. Hemming A. Bolmstedt B. Jansson J.E. Hansen B. Travis S.L. Hu S. Olofsson Identification of three N-linked glycns in the V4-V5 region of HIV-1 gp 120, dispensable for CD4-binding and fusion activity of gp 120 Arch. Virol. 134 1994 335 344
118. J. Hesselgesser M. Halks-Miller V. Del Vecchio S.C. Peiper J. Hoxie D.L. Kolson D. Taub R. Horuk CD4-independent association between HIV-1 gp120 and CXCR4: Functional chemokine receptors are expressed in human neurons Curr. Biol. 7 1997 112 121
119. C.M. Hill H. Deng D. Unutmaz V.N. Kewalramani L. Bastiani M.K. Gorny S. ZollaPazner D.R. Littman Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCRS as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor J. Virol. 71 1997 6296 6304
120. V.M. Hirsch T.R. Fuerst G. Sutter M.W. Carroll L.C. Yang S. Goldstein M. Piatak Jr. W.R. Elkins W.G. Alvord D.C. Montefiori B. Moss J.D. Lifson Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara J. Virol. 70 1996 3741 3752
121. V.M. Hirsch S. Goldstein N.A. Hynes W.R. Elkins W.T. London P.M. Zack D. Montefiori P.R. Johnson Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine J. Infect. Dis. 170 1994 51 59
122. S. Hu E. Norrby Vaccines and immunology: Overview AIDS 11 1997 S85 S86
123. S.L. Hu K. Abrams G.N. Barber P. Moran J.M. Zarling A.J. Langlois L. Kuller W.R. Morton R.E. Benveniste Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160 Science 255 1992 456 459
124. S.L. Hu P.N. Fultz H.M. McClure J.W. Eichberg E.K. Thomas J. Zarling M.C. Singhal S.G. Kosowski R.B. Swenson D.C. Anderson Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees Nature 328 1987 721 723
125. S.L. Hu P. Polacino V. Stallard J. Klaniecki S. Pennathur B.M. Travis L. Misher H. Kornas A.J. Langlois W.R. Morton R.E. Benveniste Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection Immunol. Lett. 51 1996 115 119
126. X. Huang J.J. Barchi Jr. F.D. Lung P.P. Roller P.L. Nara J. Muschik R.R. Garrity Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1111B GP120 peptide RP135 Biochemistry 36 1997 10846 10856
127. E.G. Hulskotte A.M. Geretti A.D. Osterhaus Towards an HIV-1 vaccine: Lessons from studies in macaque models Vaccine 16 1998 904 915
128. S.S. Hwang T.J. Boyle H.K. Lyerly B.R. Cullen Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1 Science 253 1991 71 74
129. T. Igarashi Y. Ami H. Yamamoto R. Shibata T. Kuwata R. Mukai K. Shinohara T. Komatsu A. Adachi M. Hayami Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: A potential candidate live-attenuated human AIDS vaccine J. Gen. Virol. 78 1997 985 989
130. T. Igarashi Y. Endo G. Englund R. Sadjadpour T. Matano C. Buckler A. Buckler-White R. Plishka T. Theodore R. Shibata M. Martin Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti CD8 mAb during a primary infection with a nonpathogenic virus Proc. Natl. Acad. Sci. USA 96 1999 14049 14054
131. Z.R. Israel P.F. Edmonson D.H. Maul S.P. O'Neil S.P. Mossman C. Thiriart L. Fabry O. Van Opstal C. Bruck F. Bex Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines J. Virol. 68 1994 1843 1853
132. K. Javaherian A.J. Langlois C. McDanal K.L. Ross L.I. Eckler C.L. Jellis A.T. Profy J.R. Rusche D.P. Bolognesi S.D. Putney Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein Proc. Natl. Acad. Sci. USA 86 1989 6768 6772
133. S.V. Joag Z. Li L. Foresman D.M. Pinson R. Raghavan W. Zhuge I. Adany C. Wang F. Jia D. Sheffer J. Ranchalis A. Watson O. Narayan Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques AIDS Res. Hum. Retroviruses 13 1997 635 645
134. S.V. Joag Z. Li L. Foresman E.B. Stephens L.J. Zhao L. Adany D.M. Pinson H.M. McClure O. Narayan Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques J. Virol. 70 1996 3189 3197
135. S.V. Joag Z.Q. Liu E.B. Stephens M.S. Smith A. Kumar Z. Li C. Wang D. Sheffer F. Jia L. Foresman L. Adany J. Lifson H.M. McClure O. Narayan Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS J. Virol. 72 1998 9069 9078
136. R.P. Johnson J.D. Lifson S.C. Czajak K.S. Cole K.H. Manson R. Glickman J. Yang D.C. Montefiori R. Montelaro M.S. Wyand R.C. Desrosiers Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal chal lenge: Inverse relationship of degree of protection with level of attenuation J. Virol. 73 1999 4952 4961
137. M.I. Johnston HIV vaccines: Problems and prospects Hosp. Pract. 32 1997 125 128
138. M.I. Johnston HIV vaccines: Problems and prospects Hosp. Pract. 32 1997 131 140
139. D.A. Katzenstein L.K. Vujcic A. Latif R. Boulos N.A. Halsey T.C. Quinn S.C. Rastogi G.V. Quitman Jr. Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans J. Acq. Immune Defic. Syndr. 3 1990 810 816
140. M.C. Keefer B.S. Graham M.J. McElrath T.J. Matthews D.M. Stablein L. Corey P.F. Wright D. Lawrence P.E. Fast K. Weinhold R.H. Hsieh D. Chernoff C. Dekker R Dolin Safety and immunogenicity of Env 2–3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59: NIAID AIDS Vaccine Evaluation Group AIDS Res. Hum. Retroviruses 12 1996 683 693
141. M.C. Keefer M. Wolff G.J. Gorse B.S. Graham L. Corey M.L. Clements-Mann N. Verani-Ketter S. Erb C.M. Smith R.B. Belshe L.J. Wagner M.J. McElrath D.H. Schwartz P. Fast Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group AIDS Res. Hum. Retroviruses 13 1997 1163 1177
142. J.J. Kim D.B. Weiner DNA gene vaccination for HIV Springer Semin. Immunopathol. 19 1997 175 194
143. F. Kirchhoff T.C. Greenough D.B. Brettler J.L. Sullivan R.C. Desrosiers Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection N. Engl. J. Med. 332 1995 228 232
144. M.R. Klein C.A. van Baalen A.M. Holwerda S.R. Kerkhof Garde R.J. Bende I.P. Keet J.K. Eeftinck-Schattenkerk A.D. Osterhaus H. Schuitemaker F. Miedema Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics J. Exp. Med. 181 1995 1365 1372
145. R.A. Koup J.T. Safrit Y. Cao C.A. Andrews G. McLeod W. Borkowsky C. Farthing D.D. Ho Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J. Virol. 68 1994 4650 4655
146. P.D. Kwong R. Wyatt E. Desjardins J. Robinson J.S. Culp B.D. Hellmig R.W. Sweet J. Sodroski W.A. Hendrickson Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1) J. Biol. Chem. 274 1999 4115 4123
147. P.D. Kwong R. Wyatt J. Robinson R.W. Sweet J. Sodroski W.A. Hendrickson Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody Nature 393 1998 648 659
148. R.A. LaCasse K.E. Follis M. Trahey J.D. Scarborough D.R. Littman J.H. Nunberg Fusion-competent vaccines: Broad neutralization of primary isolates of HIV Science 283 1999 357 362
149. R.J. Lamb-Wharton S.V. Joag E.B. Stephens O. Narayan Primate models of AIDS vaccine development AIDS 11 1997 S121 S126
150. A.J. Langlois K.J. Weinhold T.J. Matthews M.L. Greenberg D.P. Bolognesi Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus AIDS Res. Hum. Retroviruses 8 1992 1641 1652
151. G.J. LaRosa J.P. Davide K. Weinhold J.A. Waterbury A.T. Profy J.A. Lewis A.J. Langlois G.R. Dreesman R.N. Boswell P. Shadduck Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant Science 249 1990 932 935
152. R. Le Grand G. Vogt B. Vaslin P. Roques F. Theodoro A.M. Aubertin D. Dormont Specific and non-specific immunity and protection of macaques against SIV infection Vaccine 10 1992 873 879
153. M.K. Lee J. Heaton M.W. Cho Identification of determinants of interaction between CXCR4 and gp120 of a dual-tropic HIV-1DH12 isolate Virology 257 1999 290 296
154. W.R. Lee W.J. Syu B. Du M. Matsuda S. Tan A. Wolf M. Essex T.H. Lee Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1 Proc. Natl. Acad. Sci. USA 89 1992 2213 2217
155. T. Lehner Y. Wang M. Cranage L.A. Bergmeier E. Mitchell L. Tao G. Hall M. Dennis N. Cook R. Brookes L. Klavinskis I. Jones C. Doyle R. Ward Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques Nat. Med. 2 1996 767 775
156. T. Leitner B. Korber D. Robertson F. Gao B. Hahn Updated proposal of reference sequences of HIV-1 genetic subtypes B. Kober B. Hahn B. Foley J.W. Mellors T. Leitner G. Myers F. McCutchan C. Kuiken Human Retroviruses and AIDS 1997 Los Alamos National Laboratory Los Alamos III19 III24
157. C. Lekutis J.W. Shiver M.A. Liu N.L. Letvin HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha J. Immunol. 158 1997 4471 4477
158. C.K. Leonard M.W. Spellman L. Riddle R.J. Harris J.N. Thomas T.J. Gregory Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells J. Biol. Chem. 265 1990 10373 10382
159. N.L. Letvin Progress in the development of an HIV-1 vaccine Science 280 1998 1875 1880
160. N.L. Letvin J. Li M. Halloran M.P. Cranage E.W. Rud J. Sodroski Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus J. Virol. 69 1995 4569 4571
161. N.L. Letvin D.C. Montefiori Y. Yasutomi H.C. Perry M.E. Davies C. Lekutis M. Alroy D.C. Freed C.L. Lord L.K. Handt M.A. Liu J.W. Shiver Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination Proc. Natl. Acad. Sci. USA 94 1997 9378 9383
162. H.I. Levitsky Accessories for naked DNA vaccines Nat. Biotechnol. 15 1997 619 620
163. J.T. Li M. Halloran C.L. Lord A. Watson J. Ranchalis M. Fung N.L. Letvin J.G. Sodroski Persistent infection of macaques with simian-human immunodeficiency viruses J. Virol. 69 1995 7061 7067
164. Y. Li L. Luo N. Rasool C.Y. Kang Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding J. Virol. 67 1993 584 588
165. S. Liedtke M. Adamski R. Geyer A. Pfutzner H. Rubsamen-Wagmann H. Geyer Oligosaccharide profiles of HIV-2 external envelope glycoprotein: Dependence on host cells and virus isolates Glycobiology 4 1994 477 484
166. S. Liedtke R. Geyer H. Geyer Host-cell-specific glycosylation of HIV-2 envelope glycoprotein Glycoconj. J. 14 1997 785 793
167. D.R. Littman Chemokine receptors: Keys to AIDS pathogenesis? Cell 93 1998 677 680
168. B.L. Lohman M.B. McChesney C.J. Miller E. McGowan S.M. Joye K.K. Van Rompay E. Reay L. Antipa N.C. Pedersen M.L. Marthas A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge J. Virol. 68 1994 7021 7029
169. S. Lu Developing DNA vaccines against immunodeficiency viruses Curr. Top. Microbiol. Immunol. 226 1998 161 173
170. X. Lu H. Kiyono D. Lu S. Kawabata J. Torten S. Srinivasan P.J. Dailey J.R. McGhee T. Lehner C.J. Miller Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251 AIDS 12 1998 1 10
171. Y. Lu M.S. Salvato C.D. Pauza J. Li J. Sodroski K. Manson M. Wyand N. Letvin S. Jenkins N. Touzjian C. Chutkowski N. Kushner M. LeFaile L.G. Payne B. Roberts Utility of SHIV for testing HIV-1 vaccine candidates in macaques J. Acq. Immune Defic. Syndr. Hum. Retrovirol. 12 1996 99 106
172. M.D. Lubeck R. Natuk M. Myagkikh N. Kalyan K. Aldrich F. Sinangil S. Alipanah S.C. Murthy P.K. Chanda S.M. Nigida Jr. P.D. Markham S. Zolla-Pazner K. Steimer M. Wade M.S. Reitz Jr. L.O. Arthur S. Mizutani A. Davis P.P. Hung R.C. Gallo J. Eichberg M. Robert-Guroff Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization Nat. Med. 3 1997 651 658
173. P.A. Luciw Human immunodeficiency viruses and their replication B.N. Fields D.M. Knipe P.M. Howley 3rd ed. Fields Virology Vol. 2 1996 Lippincott-Raven Philadelphia 1881 1952
174. R.R. MacGregor J.D. Boyer K.E. Ugen K.E. Lacy S.J. Gluckman M.L. Bagarazzi M.A. Chattergoon Y. Baine T.J. Higgins R.B. Ciccarelli L.R. Coney R.S. Ginsberg D.B. Weiner First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response J. Infect. Dis. 178 1998 92 100
175. V.N. Malashkevich D.C. Chan C.T. Chutkowski P.S. Kim Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides Proc. Natl. Acad. Sci. USA 95 1998 9134 9139
176. M.L. Marthas S. Sutjipto J. Higgins B. Lohman J. Torten P.A. Luciw P.A. Marx N.C. Pedersen Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV J. Virol. 64 1990 3694 3700
177. J.R. Mascola M.G. Lewis G. Stiegler D. Harris T.C. VanCott D. Hayes M.K. Louder C.R. Brown C.V. Sapan S.S. Frankel Y. Lu M.L. Robb H. Katinger D.L. Birx Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies J. Virol. 73 1999 4009 4018
178. J.R. Mascola S.W. Snyder O.S. Weislow S.M. Belay R.B. Belshe D.H. Schwartz M.L. Clements R. Dolin B.S. Graham G.J. Gorse M.C. Keefer M.J. McElrath M.C. Walker K.F. Wagner J.G. McNeil F.E. McCutchan D.S. Burke Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1: The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group J. Infect. Dis. 173 1996 340 348
179. T.J. Matthews Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development AIDS Res. Hum. Retroviruses 10 1994 631 632
180. M.J. McElrath L. Corey D. Berger M.C. Hoffman S. Klucking J. Dragavon E. Peterson P.D. Greenberg Immune responses elicited by recombinant vacciniahuman immunodeficiency virus (HIV) envelope and HIV envelope protein: Analysis of the durability of responses and effect of repeated boosting J. Infect. Dis. 169 1994 41 47
181. M.J. McElrath L. Corey P.D. Greenberg T.J. Matthews D.C. Montefiori L. Rowen L. Hood J.J. Mullins Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen Proc. Natl. Acad. Sci. USA 93 1996 3972 3977
182. M.J. McElrath R.F. Siliciano K.J. Weinhold HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation AIDS Res. Hum. Retroviruses 13 1997 211 216
183. K.H. Mills M. Page W.L. Chan P. Kitchin E.J. Stott F. Taffs W. Jones J. Rose C. Ling P. Silvera Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28derived recombinant env and gag proteins J. Med. Primatol. 21 1992 50 58
184. H. Mo L. Stamatatos J.E. Ip C.F. Barbas P.W. Parren D.R. Burton J.P. Moore D.D. Ho Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12 J. Virol. 71 1997 6869 6874
185. D.C. Montefiori B.S. Graham S. Kliks P.F. Wright Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160: NIAID AIDS Vaccine Clinical Trials Network J. Clin. Immunol. 12 1992 429 439
186. J.P. Moore D.R. Burton HIVA neutralizing antibodies: How full is the bottle? Nat. Med. 5 1999 142 144
187. J.P. Moore D.D. Ho HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells AIDS 9 1995 S117 S136
188. J.P. Moore A. Trkola T. Dragic Co-receptors for HIV-1 entry Curr. Opin. Immunol. 9 1997 551 562
189. S.P. Mossman F. Bex P. Berglund J. Arthos S.P. O'Neil D. Riley D.H. Maul C. Bruck P. Momin A. Burny P.N. Fultz J.L. Mullins P. Liliestrom E.A. Hoover Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine J. Virol. 70 1996 1953 1960
190. M. Murphey-Corb L.N. Martin B. Davison-Fairburn R.C. Montelaro M. Miller M. West S. Ohkawa G.B. Baskin J.Y. Zhang S.D. Putney A formalininactivated whole SIV vaccine confes protection in macaques Science 246 1989 1293 1297
191. M. Murphey-Corb R.C. Montelaro M.A. Miller M. West L.N. Martin B. DavisonFairburn S. Ohkawa G.B. Baskin J.Y. Zhang G.B. Miller Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys AIDS 5 1991 655 662
192. K.K. Murthy E.K. Cobb S.R. Rouse H.M. McClure J.S. Payne M.T. Salas G.R. Michalek Active and passive immunization against HIV type 1 infection in chimpanzees AIDS Res. Hum. Retroviruses 14 Suppl 3 1998 S271 S276
193. G. Myers R. Lenroot HIV glycosylation: What does it portend? AIDS Res. Hum. Retroviruses 8 1992 1459 1460
194. E.E. Nakayama T. Shioda M. Tatsumi X. Xin D. Yu S. Ohgimoto A. Kato Y. Sakai Y. Ohnishi Y. Nagai Importance of the N-glycan in the V3 loop of HIV-1 envelope protein for CXCR-4- but not CCR-5-dependent fusion FEBS Lett. 426 1998 367 372
195. P.L. Nara W.G. Robey S.W. Pyle W.C. Hatch N.M. Dunlop J.W. Bess Jr. J.C. Kelliher L.O. Arthur P.J. Fischinger Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies J. Virol. 62 1988 2622 2628
196. F.J. Novembre M. Saucier D.C. Anderson S.A. Klumpp S.P. O'Neil C.R. Brown C.E. Hart P.C. Guenthner R.B. Swenson H.M. McClure Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1 J. Virol. 71 1997 4086 4091 2nd
197. W.A. O'Brien Y. Koyanagi A. Namazie J.Q. Zhao A. Diagne K. Idler J.A. Zack I.S. Chen HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain Nature 348 1990 69 73
198. Ogert, R., Lee, M.K., Ross, W., White-Buckler, A., Martin, M.A. and Cho, M.W. (manuscript in preparation)
199. S. Ohgimoto T. Shioda K. Mori E.E. Nakayama H. Hu Y. Nagai Locationspecific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity J. Virol. 72 1998 8365 8370
200. R. Pal F. di Matzo Veronese B.C. Nair S. Rittenhouse G. Hoke S. Mumbauer M.G. Sarngadharan Glycoprotein of human immunodeficiency virus type 1 synthesized in chronically infected Molt3 cells acquires heterogeneous oligosaccharide structures Biochem. Biophys. Res. Commun. 196 1993 1335 1342
201. T.J. Palker M.E. Clark A.J. Langlois T.J. Matthews K.J. Weinhold R.R. Randall D.P. Bolognesi B.F. Haynes Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides Proc. Natl. Acad. Sci. USA 85 1988 1932 1936
202. M.J. Papandreou E. Fenouillet Effect of changes in the glycosylation of the human immunodeficiency virus type 1 envelope on the immunoreactivity and sensitivity to thrombin of its third variable domain Virology 241 1998 163 167
203. P.W. Parren M.C. Gauduin R.A. Koup P. Poignard P. Fisicaro D.R. Burton Q.J. Sattentau Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design Immunol. Lett. 57 1997 105 112
204. P.W. Parren L. Mondor D. Naniche H.J. Ditzel P.J. Klasse D.R. Burton Q.J. Sattentau Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity J. Virol. 72 1998 3512 3519
205. G. Pialoux J.L. Excler Y. Riviere G. Gonzalez-Canali V. Feuillie P. Coulaud J.C. Gluckman T.J. Matthews B. Meignier M.P. Kieny A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI) AIDS Res. Hum. Retroviruses 11 1995 373 381
206. A. Pinter W.J. Honnen S.C. Kayman O. Trochev Z. Wu Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120 Vaccine 16 1998 1803 1811
207. A. Printer W.J. Honnen S.A. Tilley C. Bona H. Zaghouani M.K. Gorny S. Zolla-Pazner Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1 J. Virol. 63 1989 2674 2679
208. L.A. Pinto J. Sullivan J.A. Berzofsky M. Clerici H.A. Kessler A.L. Landay G.M. Shearer ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids J. Clin. Invest. 96 1995 867 876
209. O. Pleskoff N. Sol B. Labrosse M. Alizon Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR4 (fusin) J. Virol. 71 1997 3259 3262
210. P. Poignard P.J. Klasse Q.J. Sattentau Antibody neutralization of HIV-1 Immunol. Today 17 1996 239 246
211. P. Polacino V. Stallard D.C. Montefiori C.R. Brown B.A. Richardson W.R. Morton R.E. Benveniste S.L. Hu Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines J. Virol. 73 1999 3134 3146
212. A.M. Prince H. Reesink D. Pascual B. Horowitz I. Hewlett K.K. Murthy K.E. Cobb J.W. Eichberg Prevention of HIV infection by passive immunization with HIV immunoglobulin AIDS Res. Hum. Retroviruses 7 1991 971 973
213. P. Putkonen C. Nilsson L. Walther L. Ghavamzadeh K. Hild K. Broliden G. Biberfeld R. Thorstensson Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys J. Med. Primatol. 23 1994 89 94
214. P. Putkonen R. Thorstensson J. Albert K. Hild E. Norrby P. Biberfeld G. Biberfeld Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection AIDS 4 1990 783 789
215. P. Putkonen R. Thorstensson L. Walther J. Albert L. Akerblom O. Granquist G. Wadell E. Norrby G. Biberfeld Vaccine protection against HIV-2 infection in cynomolgus monkeys AIDS Res. Hum. Retroviruses 7 1991 271 277
216. S.D. Putney J. Rusche K. Javaherian T. Matthews D. Bolognesi Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development Biotechnology 14 1990 81 110
217. M. Quesada-Rolander B. Makitalo R. Thorstensson Y.J. Zhang E. Castanos-Velez G. Biberfeld P. Putkonen Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope AIDS Res. Hum. Retroviruses 12 1996 993 999
218. K.A. Reimann J.T. Li R. Veazey M. Halloran I.W. Park G.B. Karlsson J. Sodroski N.L. Letvin A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys J. Virol. 70 1996 6922 6928
219. J.N. Reitter R.C. Desrosiers Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates invariable regions 1 and 2 of the surface envelope protein J. Virol. 72 1998 5399 5407
220. J.N. Reitter R.E. Means R.C. Desrosiers A role for carbohydrates in immune evasion in AIDS Nat. Med. 4 1998 679 684
221. T. Richardson Jr. B.L. Stryjewski C.C. Broder J.A. Hoxie J.R. Mascola P.L. Earl R.W. Doms Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein J. Virol. 70 1996 753 762
222. C. Rinaldo X.L. Huang Z.F. Fan M. Ding L. Beltz A. Logar D. Panicali G. Mazzara J. Liebmann M. Cottrill High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors J. Virol. 69 1995 5838 5842
223. C.D. Rizzuto R. Wyatt N. Hernandez-Ramos Y. Sun P.D. Kwong W.A. Hendrickson J. Sodroski A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding Science 280 1998 1949 1953
224. P. Roben J.P. Moore M. Thali J. Sodroski C.F. Barbas D.R. Burton Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 J. Virol. 68 1994 4821 4828 3rd
225. H.L. Robinson DNA vaccines for immunodeficiency viruses AIDS 11 1997 S109 5119
226. T.M. Ross B.R. Cullen The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop Proc. Natl. Acad. Sci. USA 95 1998 7682 7686
227. J.L. Rossio M.T. Esser K. Suryanarayana D.K. Schneider J.W. Bess Jr. G.M. Vasquez T.A. Wiltrout E. Chertova M.K. Grimes Q. Sattentau L.O. Arthur L.E. Henderson J.D. Lifson Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins J. Virol. 72 1998 7992 8001
228. S. Rowland-Jones T. Dong P. Krausa J. Sutton H. Newell K. Ariyoshi F. Gotch S. Sabally T. Corrah J. Kimani K. MacDonald F. Plummer J. Ndinya-Achola H. Whittle A. McMichael The role of cytotoxic T-cells in HIV infection Dev. Biol. Stand. 92 1998 209 214
229. S. Rowland-Jones J. Sutton K. Ariyoshi T. Dong F. Gotch S. McAdam D. Whitby S. Sabally A. Gallimore T. Corrah HIV-specific cytotoxic T-cells in HIVexposed but uninfected Gambian women Nat. Med. 1 1995 59 64
230. S.L. Rowland-Jones T. Dong L. Dorrell G. Ogg P. Hansasuta P. Krausa J. Kimani S. Sabally K. Ariyoshi J. Oyugi K.S. MacDonald J. Bwayo H. Whittle F.A. Plummer A.J. McMichael Broadly cross-reactive HIV-specific cytotoxic T lymphocytes in highly-exposed persistently seronegative donors Immunol. Lett. 66 1999 9 14
231. S.L. Rowland-Jones T. Dong K.R. Fowke J. Kimani P. Krausa H. Newell T. Blanchard K. Ariyoshi J. Oyugi E. Ngugi J. Bwayo K.S. MacDonald A.J. McMichael F.A. Plummer Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi J. Clin. Invest. 102 1998 1758 1765
232. R.M.W.B.T. Ruprecht A. Li S. Ayehunie Y. Hu V. Liska R. Rasmussen P.L. Sharma Live attenuate HIV as a vaccine for AIDS: Pros and cons Semin. Virol. 7 1996 147 155
233. J.R. Rusche K. Javaherian C. McDanal J. Petro D.L. Lynn R. Grimaila A. Langlois R.C. Gallo L.O. Arthur P.J. Fischinger Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 Proc. Natl. Acad. Sci. USA 85 1988 3198 3202
234. D. Salmon-Ceron J.L. Excler D. Sicard P. Blanche L. Finkielstzjen J.C. Gluckman B. Autran T.J. Matthews B. Meignier M.P. Kieny Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers AIDS Res. Hum. Retroviruses 11 1995 1479 1486
235. L.S. Sawyer M.T. Wrin L. Crawford-Miksza B. Potts Y. Wu P.A. Weber R.D. Alfonso C.V. Hanson Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated J. Virol. 68 1994 1342 1349
236. M. Schawaller G.E. Smith J.J. Skehel D.C. Wiley Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV Virology 172 1989 367 369
237. K. Schonning B. Jansson S. Olofsson J.O. Nielsen J.S. Hansen Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer Virology 218 1996 134 140
238. A. Schultz Encouraging vaccine results from primate models of HIV type 1 infection AIDS Res. Hum. Retroviruses 14 Suppl 3 1998 S261 5263
239. A.M. Schultz E.J. Stott Primate models for AIDS vaccines AIDS 8 1994 S203 5212
240. R. Shibata T. Igarashi N. Haigwood A. Buckler-White R. Ogert W. Ross R. Willey M.W. Cho M.A. Martin Neutralizing antibody directed against the HIV1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys Nat. Med. 5 1999 204 210
241. R. Shibata M. Kawamura H. Sakai M. Hayami A. Ishimoto A. Adachi Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells J. Virol. 65 1991 3514 3520
242. R. Shibata F. Maldarelli C. Siemon T. Matano M. Parta G. Miller T. Fredrickson M.A. Martin Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing J. Infect. Dis. 176 1997 362 373
243. R. Shibata C. Siemon S.C. Czajak R.C. Desrosiers M.A. Martin Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus J. Virol. 71 1997 8141 8148
244. T. Shioda J.A. Levy C. Cheng-Mayer Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1 Proc. Natl. Acad. Sci. USA 89 1992 9434 9438
245. J.W. Shiver M.E. Davies Y. Yasutomi H.C. Perry D.C. Freed N.L. Letvin M.A. Liu Anti-HIV env immunities elicited by nucleic acid vaccines Vaccine 15 1997 884 887
246. R.J. Smyth Y. Yi A. Singh R.G. Collman Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate J. Virol. 72 1998 4478 4484
247. R.F. Speck K. Wehrly E.J. Platt R.E. Atchison I.F. Charo D. Kabat B. Chesebro M.A. Goldsmith Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop J. Virol. 71 1997 7136 7139
248. K.S. Steimer N.L. Haigwood Importance of conformation on the neutralizing antibody response to HIV- I gp120 Biotechnol. Ther. 2 1991 63 89
249. K.S. Steimer C.J. Scandella P.V. Skiles N.L. Haigwood Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120 Science 254 1991 105 108
250. R.M. Steinman R.N. Germain Antigen presentation and related immunological aspects of HIV-1 vaccines AIDS 12 1998 S97 5112
251. E.J. Stott Anti-cell antibody in macaques Nature 353 1991 393
252. E.J. Stott G.C. Schild Strategies for AIDS vaccines J. Antimicrob. Chemotber. 37 Suppl B 1996 185 198
253. E.J. Stott W.L. Chan K.H. Mills M. Page F. Taffs M. Cranage P. Greenaway P. Kitchin Preliminary report: Protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine Lancet 336 1990 1538 1541
254. J. Stott S.L. Hu N. Almond Candidate vaccines protect macaques against primate immunodeficiency viruses AIDS Res. Hum. Retroviruses 14 Suppl 3 1998 S265 S270
255. A. Suhrbier Multi-epitope DNA vaccines Immunol. Cell. Biol. 75 1997 402 408
256. N. Sullivan Y. Sun Q. Sattentau M. Thali D. Wu G. Denisova J. Gershoni J. Robinson J. Moore J Sodroski CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization J. Virol. 72 1998 4694 4703
257. S. Sutjipto T. Kodama J. Yee A. Geetie M. Jennings R.C. Desrosiers P.A. Marx Characterization of monoclonal antibodies that distinguish simian immunodeficiency virus isolates from each other and from human immunodeficiency virus types 1 and 2 J. Gen. Virol. 71 1990 247 249
258. K. Tan J. Liu J. Wang S. Shen M. Lu Atomic structure of a thermostable subdomain of HIV-1 gp41 Proc. Natl. Acad. Sci. USA 94 1997 12303 12308
259. J. Tartaglia J.L. Excler R. El Habib K. Limbach B. Meignier S. Plotkin M. Klein Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV AIDS Res. Hum. Retroviruses 14 Suppl 3 1998 S291 S298
260. M. Thali J.P. Moore C. Furman M. Charles D.D. Ho J. Robinson J. Sodroski Characterization of conserved human immunodeficiency virus type I gp120 neutralization epitopes exposed upon gp120-CD4 binding J. Virol. 67 1993 3978 3988
261. A. Trkola T. Dragic J. Arthos J.M. Binley W.C. Olson G.P. Allaway C. Cheng-Mayer J. Robinson P.J. Maddon J.P. Moore CD4-dependent, antibody sensitive interactions between HIV- 1 and its co-receptor CCR-5 Nature 384 1996 184 187
262. A. Trkola A.B. Pomales H. Yuan B. Korber P.J. Maddon G.P. Allaway H. Katinger C.F. Barbas D.R. Burton D.D. Ho Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG J. Virol. 69 1995 6609 6617 3rd
263. A. Trkola M. Purtscher T. Muster C. Ballaun A. Buchacher N. Sullivan K. Srinivasan J. Sodroski J.P. Moore H. Katinger Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 J. Virol. 70 1996 1100 1108
264. B.G. Turner M.F. Summers Structural biology of HIV J. Mol. Biol. 285 1999 1 32
265. K.E. Ugen S.B. Nyland J.D. Boyer C. Vidal L. Lera S. Rasheid M. Chattergoon M.L. Bagarazzi R. Ciccarelli T. Higgins Y. Baine R. Ginsgerg R.R. Macgregor D.B. Weiner DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans Vaccine 16 1998 1818 1821
266. T.C. VanCott F.R. Bethke D.S. Burke R.R. Redfield D.L. Birx Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines J. Immunol. 155 1995 4100 4110
267. P. Verani F. Titti F. Corrias R. Belli S. Di Fabio A. Geraci M. Konga-Mogtomo M.T. Maggiorella L. Sernicola Vaccines against HIV J. Biol. Regul. Homeost. Agents 11 1997 82 87
268. L.K. Vujcic G.V. Quinnan Jr. Preparation and characterization of human HIV type 1 neutralizing reference sera AIDS Res. Hum. Retroviruses 11 1995 783 787
269. R. Wagner L. Deml V. Teeuwsen J. Heeney S. Yiming H. Wolf A recombinant HIV-1 virus-like particle vaccine: From concepts to a field study Antibiot. Chemother. 48 1996 68 83
270. B. Wahren M. Brytting DNA increases the potency of vaccination against infectious diseases Curr. Opin. Chem. Biol. 1 1997 183 189
271. B.D. Walker M. Kowalski W.C. Goh K. Kozarsky M. Krieger C. Rosen L. Rohrschneider W.A. Haseltine J. Sodroski Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine Proc. Natl. Acad. Sci. USA 84 1987 8120 8124
272. C.D. Weiss J.A. Levy J.M. White Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 paticles J. Virol. 64 1990 5674 5677
273. R.A. Weiss P.R. Clapham J.N. Weber A.G. Dalgleish L.A. Lasky P.W. Berman Variable and conserved neutralization antigens of human immunodeficiency virus nature 324 1986 572 575
274. W. Weissenhorn A. Dessen S.C. Harrison J.J. Skehel D.C. Wiley Atomic structure of the ectodomain from HIV-1 gp41 Nature 387 1997 426 430
275. T.N. Wells A.E. Proudfoot C.A. Power M. Marsh Chemokine receptors-The new frontier for AIDS research Chem. Biol. 3 1996 603 609
276. P. Westervelt H.E. Gendelman L. Ratner Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes Proc. Natl. Acad. Sci. USA 88 1991 3097 3101
277. R.L. Willey R. Shibata E.O. Freed M.W. Cho M.A. Martin Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures J. Virol. 70 1996 6431 6436
278. R.L. Willey D.H. Smith L.A. Lasky T.S. Theodore P.L. Earl B. Moss D.J. Capon M.A. Martin In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity J. Virol. 62 1998 139 147
279. L. Wu N.P. Gerard R. Wyatt H. Choe C. Parolin N. Ruffing A. Borsetti A.A. Cardoso E. Desjardin W. Newman C. Gerard J. Sodroski CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 Nature 384 1996 179 183
280. M.S. Wyand K.H. Manson A.A. Lackner R.C. Desrosiers Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus nat. Med. 3 1997 32 36
281. R. Wyatt J. Sodroski The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens Science 280 1998 1884 1888
282. R. Wyatt P.D. Kwong E. Desjardins R.W. Sweet J. Robinson W.A. Hendrickson J.G. Sodroski The antigenic structure of the HIV gp120 envelope glycoprotein Nature 393 1998 705 711
283. R. Wyatt J. Moore M. Accola E. Desjardin J. Roginson J. Sodroski Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding J. Virol. 69 1995 5723 5733
284. Y. Yasutomi H.L. Robinson S. Lu F. Mustafa C. Lekutis J. Arthos J.I. Mullins G. Voss K. Manson M. Wyand N.L. Letvin Simian immunodeficiency virusspecific cutotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys J. Virol. 70 1996 678 681
285. S. Zolla-Pazner M. Lubeck S. Xu S. Burda R.J. Natuk F. Sinangil K. Steimer R.C. Gallo J.W. Eichberg T. Matthews M. Robert-Guroff Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees J. Virol. 72 1998 1052 1059